Close



Apr 18, 2024 08:00AM
Mar 11, 2024 08:02AM
Mar 11, 2024 08:00AM
Mar 6, 2024 05:00PM
Mar 4, 2024 06:11AM
Mar 4, 2024 01:32AM
Mar 1, 2024 04:58PM BioVie Inc. Announces Proposed Public Offering of Common Stoc
Mar 1, 2024 08:02AM
Mar 1, 2024 08:00AM
Feb 6, 2024 08:00AM
Nov 29, 2023 08:01AM
Nov 29, 2023 08:00AM
Oct 25, 2023 12:30PM
Oct 19, 2023 07:30AM BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD
Mar 14, 2023 08:00AM
Feb 21, 2023 08:00AM
Dec 29, 2022 08:30AM
Dec 7, 2022 08:13AM
Dec 7, 2022 08:00AM
Dec 6, 2022 06:22AM
Dec 6, 2022 06:00AM BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline
Dec 5, 2022 05:02PM
Dec 5, 2022 05:00PM
Nov 29, 2022 08:00AM
Nov 15, 2022 08:00AM
Oct 24, 2022 08:00AM
Oct 19, 2022 06:01AM
Oct 19, 2022 06:00AM BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled
Oct 4, 2022 08:00AM
Sep 7, 2022 07:07AM
Sep 7, 2022 06:00AM
Jun 23, 2022 08:02AM
Jun 23, 2022 08:00AM
Mar 10, 2022 08:00AM
Mar 9, 2022 04:05PM BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference
Jan 20, 2022 08:00AM
Dec 9, 2021 08:00AM
Dec 1, 2021 08:00AM
Nov 4, 2021 08:00AM
Nov 1, 2021 08:10AM
Nov 1, 2021 08:00AM
Oct 26, 2021 08:07AM BioVie Inc. (BIVI) Receives FDA Clearance to Commence Phase 2 Trials Assessing NE3107’s Pro-motoric Activity in Parkinson’s Disease
Oct 26, 2021 08:00AM
Oct 13, 2021 08:00AM
Sep 22, 2021 08:00AM
Sep 15, 2021 04:01PM
Aug 11, 2021 01:14PM
Aug 9, 2021 05:20AM
Aug 8, 2021 09:28PM BioVie Inc. Announces Pricing of Public Offering of Common Stock
Aug 6, 2021 05:30PM

377,482 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All